BioSpecifics announces postive data from Xiaflex Phase IIa study BioSpecifics (BSTC) announced positive, statistically significant top-line data from the Phase IIa study of Xiaflex for the potential treatment of frozen shoulder. This open-label, controlled dose-ranging Phase IIa study was conducted by BioSpecifics' strategic partner Auxilium (AUXL) and was designed to assess the safety and efficacy of Xiaflex for the treatment of Stage 2 unilateral idiopathic frozen shoulder in comparison to an exercise-only control group. Both the 0.58mg and 0.58mg dosing arms showed positive, statistically significant improvement from baseline in forward flexion vs. the exercise-only group. There were no drug-related serious adverse events reported and all treatment-related adverse events were consistent with XIAFLEX use in other approved and potential indications.
News For BSTC;AUXL From The Last 14 Days
Check below for free stories on BSTC;AUXL the last two weeks.